Library Open Repository

Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses

Downloads

Downloads per month over past year

Tremlett, H and van der Mei, IAF and Pittas, F and Blizzard, CL and Paley, G and Dwyer, T and Taylor, BV and Ponsonby, AL (2008) Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety, 17 (6). pp. 565-576. ISSN 1053-8569

[img] PDF
Tremlett_Pharmacoepidem_Drug_Saf.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.

Abstract

Background Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS). However, predictors of adherence are not well understood; past studies lacked lifestyle factors such as alcohol use and predictors of missed doses have not been evaluated. We examined both levels of non-adherence—stopping IMD and missing doses. Methods This longitudinal prospective study followed a population-based cohort (n=199) of definite MS patients in Southern Tasmania (January 2002 to April 2005, source population 226 559) every 6 months. Baseline factors (demographic, clinical, psychological and cognitive) affecting adherence were examined by logistic regression and a longitudinal analysis (generalized estimating equation (GEE)). Results Of the 97 patients taking an IMD (mean follow-up=2.4 years), 73% (71/97) missed doses, with 1 in 10 missing>10 doses in any 6-month period. Missed doses were positively associated with alcohol amount consumed per session ( p=0.008). A history of missed doses predicted future missed doses ( p<0.0005). Over one-quarter (27/97) stopped their current IMD, which was associated with lower education levels ( p=0.032) and previous relapses ( p=0.05). No cognitive or psychological test predicted adherence. Conclusions There were few strong predictors of missed doses, although people with MS consuming more alcoholic drinks per session are at a higher risk of missing doses. Divergent factors influenced the two levels of non-adherence indicating the need for a multifaceted approach to improving IMD adherence. In addition, missed doses should be assessed and incorporated into clinical trial design and clinical practice as poor adherers could impact on clinical outcomes.

Item Type: Article
Keywords: multiple sclerosis; adherence; compliance; immunomodulatory treatment; beta-interferon; glatiramer acetate
Journal or Publication Title: Pharmacoepidemiology and Drug Safety
Page Range: pp. 565-576
ISSN: 1053-8569
Identification Number - DOI: 10.1002/pds.1593
Additional Information: The definitive published version is available online at: http://interscience.wiley.com
Date Deposited: 09 Dec 2008 22:23
Last Modified: 18 Nov 2014 03:54
URI: http://eprints.utas.edu.au/id/eprint/8101
Item Statistics: View statistics for this item

Repository Staff Only (login required)

Item Control Page Item Control Page